Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 12 July 2024, including: Q1’s top 10 drugs; Pfizer Inc.’s R&D leadership succession; Eli Lilly and Company bolsters IBD pipeline; first half deal volume up but value down; and EU firms’ China sentiment plummets.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Top 10 Drugs Q1 2024: Keytruda Reigns, Trikafta Debuts" - Scrip, 5 July, 2024.)
(Also see "Pfizer’s Dolsten Plans Exit, Ushering In R&D Transition" - Scrip, 9 July, 2024.)
(Also see "Lilly To Bolster IBD Pipeline With $3.2bn Morphic Bid" - Scrip, 8 July, 2024.)
(Also see "Deal Volume Up, Value Down During The First Half" - Scrip, 10 July, 2024.)
(Also see "EU Firms' China Sentiment Plummets, China Go-Global Push Hits Reality Check" - Scrip, 5 July, 2024.)
